Wealth Enhancement Trust Services’s Keros Therapeutics KROS Stock Holding History

Wealth Enhancement Trust Services’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$685	Buy	+64	New	+$713	﹤0.01%	1194

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wealth Enhancement Trust Services's KROS Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Keros Therapeutics (KROS) in Q2 2026: 64 shares worth $685. The stake represents ﹤0.01% of the portfolio and ranks #1194 among its holdings.

62 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Wealth Enhancement Trust Services held 64 shares of Keros Therapeutics worth $685 as of Q2 2026.
Keros Therapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
Keros Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1194 holding.
62 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.